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Background: Chronic myeloid leukemia (CML) pathogenesis is mainly driven by the oncogenic breakpoint cluster
region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) fusion protein. Since BCR-ABL displays abnormal
constitutive tyrosine kinase activity, therapies using tyrosine kinase inhibitors (TKis) such as imatinib represent a major
breakthrough for the outcome of CML patients. Nevertheless, the development of TKi resistance and the persistence of
leukemia stem cells (LSCs) remain barriers to cure the disease, justifying the development of novel therapeutic
approaches. Since the activity of histone deacetylase (HDAC) is deregulated in numerous cancers including CML, pan-
HDAC inhibitors may represent promising therapeutic regimens for the treatment of CML cells in combination with TKi.
Results: We assessed the anti-leukemic activity of a novel hydroxamate-based pan-HDAC inhibitor MAKV-8, which
complied with the Lipinski’s “rule of five,” in various CML cells alone or in combination with imatinib. We validated the
in vitro HDAC-inhibitory potential of MAKV-8 and demonstrated efficient binding to the ligand-binding pocket of
HDAC isoenzymes. In cellulo, MAKV-8 significantly induced target protein acetylation, displayed cytostatic and cytotoxic
properties, and triggered concomitant ER stress/protective autophagy leading to canonical caspase-dependent
apoptosis. Considering the specific upregulation of selected HDACs in LSCs from CML patients, we investigated the
differential toxicity of a co-treatment with MAKV-8 and imatinib in CML versus healthy cells. We also showed that
beclin-1 knockdown prevented MAKV-8-imatinib combination-induced apoptosis. Moreover, MAKV-8 and imatinib co-
treatment synergistically reduced BCR-ABL-related signaling pathways involved in CML cell growth and survival. Since
our results showed that LSCs from CML patients overexpressed c-MYC, importantly MAKV-8-imatinib co-treatment
reduced c-MYC levels and the LSC population. In vivo, tumor growth of xenografted K-562 cells in zebrafish was
completely abrogated upon combined treatment with MAKV-8 and imatinib.
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Conclusions: Collectively, the present findings show that combinations HDAC inhibitor-imatinib are likely to overcome
drug resistance in CML pathology.
Keywords: Epigenetic regulation, Tyrosine kinase inhibitor, Computational docking, Autophagy, Apoptosis,
Endoplasmic reticulum stressBackground
Chronic myeloid leukemia (CML) is a clonal myeloprolifer-
ative malignancy accounting for 15% of newly diagnosed
leukemia cases in adults [1]. CML pathogenesis is mainly
driven by the translocation t(9;22)(q34;11) between the
breakpoint cluster region (BCR) and the Abelson murine
leukemia viral oncogene homolog 1 (ABL) genes. The
resulting fusion gene is translated into the oncogenic BCR-
ABL protein with abnormal constitutive tyrosine kinase
activity, which stimulates tumor cell proliferation and
survival [2]. Accordingly, BCR-ABL-positive CML patients
are currently treated with tyrosine kinase inhibitors (TKis)
including imatinib. TKis effectively block downstream
BCR-ABL signaling pathways and eliminate most CML
cells [3]. Nevertheless, such therapeutic regimens are asso-
ciated with severe side effects, as well as the development
of TKi resistance, partly due to the reservoir of TKi-
insensitive quiescent leukemic stem cells (LSCs) [4, 5].
Therefore, novel therapeutic approaches are required to
overcome these limitations and effectively cure CML pa-
tients. Combining imatinib with epigenetic modulators has
emerged as a promising strategy for improving anti-
leukemic therapy. Accordingly, TKi-HDACi combinations
have been shown to induce synergistic anti-CML effects
and LSC eradication [6].
Histone deacetylases (HDACs) catalyze the removal of
acetyl groups from lysine residues of various histones and
non-histone protein targets. They thus act as important
regulators of gene expression and are implicated in a pleth-
ora of cellular processes [7]. Nowadays, it is established that
aberrant activation or overexpression of HDAC isoenzymes
trigger disruptions of the functional acetylation landscape,
therefore contributing to the development of numerous
cancers including CML [8, 9]. Since HDACs are considered
to be attractive targets for cancer prevention and therapy,
pan-HDAC inhibitors (HDACis) represent a powerful class
of epigenetically active therapeutic drugs that have already
demonstrated promising anti-cancer activities in pre-
clinical studies and are undergoing clinical trials for many
cancers [10, 11]. Four HDACis have achieved Food and
Drug Administration approval: class I selective- (FK-228)
or pan-HDACis [suberoylanilide hydroxamic acid (SAHA),
PXD-101, and LBH-589] [12]. In particular, SAHA has
been repeatedly reported to enhance the cytotoxicity of
various chemotherapeutic drugs including TKis such as
imatinib [13] and dasatinib [14].MAKV-8, characterized by a linker of 6-methylene
units and a CAP group with arylisoxazole, has been ini-
tially reported to display an IC50 value of 2 pM towards
HDAC3 and HDAC6 in vitro, and its anti-proliferative
activity against pancreatic cancer cells was similar to that
of SAHA [15]. However, its HDAC-inhibitory properties
were never tested in cellulo, and the molecular mechan-
ism through which MAKV-8 exhibits anti-cancer effects
has not been characterized. In this study, we demon-
strated that the pan-HDACi MAKV-8 in combination
with imatinib displays anti-leukemic properties, which
are likely to lower the burden of resistance in CML
pathology.
Results
In vitro HDAC inhibition by MAKV-8
First, we assessed the in vitro HDAC inhibitory potential of
MAKV-8 using SAHA as a reference compound (Fig. 1).
MAKV-8 inhibited total HDAC, as well as recombinant
HDAC1 and HDAC6 deacetylase activities with IC50 values
of 5.8, 2.6, and 11.4 nM, respectively, suggesting the inhib-
ition of multiple deacetylase activities. Notably, about 10%
of the total HDAC activity remained with 2 μM SAHA or
0.1 μM MAKV-8 (Fig. 2a).
In silico prediction of the drug-likeness characteristics of
MAKV-8
In silico predictions showed that MAKV-8 had low lipo-
philicity, as characterized by a miLogP coefficient below
5 and a logD7.4 of 2.8, which is a major criterion for or-
ally active drugs. This compound expressed a topological
polar surface area of 142.79 combined with a molecular
weight of 446.5 Da; further, 4 and 10 hydrogen bond do-
nors and acceptors, respectively, were recognized. These
parameters imply free diffusion over the cell membrane.
Interestingly, MAKV-8 displayed a favorable intestinal
absorption parameter and plasma protein binding poten-
tial compared to PXD-101, predicting a good bioavailabil-
ity (Table 1). Altogether, MAKV-8 displayed favorable
drug-likeness parameters and a low predicted toxicity risk,
similar to FDA-approved pan-HDACis.
MAKV-8 efficiently binds to the ligand-binding pocket of
HDAC isoenzymes
A docking simulation on a panel of human HDAC iso-
forms frequently associated with tumorigenesis indicated
Fig. 1 Chemical structures of MAKV-6, MAKV-7, MAKV-8, MAKV-10, and MAKV-12 and the reference HDACi, SAHA. The prototypical
pharmacophoric model of an HDACi is constituted by the zinc binding group, the hydrophobic linker region, and the cap group. MAKV-6 and
MAKV-7 lack the linker portion; MAKV-10 and MAKV-12 substitute the hydroxamate group with a methyl ester group and were obtained as
synthesis intermediates
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region of MAKV-8 established efficient interactions in
the ligand-binding pocket of all HDAC isoenzymes,
whereas its CAP group interacted with loops around the
ligand-binding pocket (Fig. 2b; Additional file 1: Figure S1).
Qualitative molecular analyses demonstrated that MAKV-8
displayed more potent binding affinities than SAHA for all
tested HDACs, with average values of − 7.1 and − 6.2 kcal/
mol, respectively, and suggested a moderately different
HDAC-inhibitory profile between MAKV-8 and SAHA,
since binding affinity energy values were similar for certain
HDACs and distinct for others (Table 2).
MAKV-8 significantly induced target protein acetylation
To determine whether MAKV-8 acted as an HDACi in
cellulo, we next analyzed its effect compared to SAHA
on the acetylation of histone H4, a nuclear substrate of
class I, II, and IV HDACs, and α-tubulin, a cytoplasmic
substrate of HDAC6. In K-562 cells, MAKV-8 strongly
induced α-tubulin and histone H4 acetylation in aconcentration-dependent manner, starting from 5 and 1
μM, respectively (Fig. 3a). SAHA increased such protein
acetylation in a similar manner to that observed with
MAKV-8, albeit at lower concentrations. Noteworthy,
EC50 values suggested that MAKV-8 displayed increased
selectivity against nuclear HDACs targeting histone H4
compared to HDAC6 targeting α-tubulin, whereas SAHA
acted similarly on both targets (Table 3). Next, kinetic ana-
lysis of α-tubulin and histone H4 acetylation status showed
a rapid and time-dependent increase in protein acetylation
beginning at 2 h after MAKV-8 treatment, with a peak oc-
curring between 8 and 24 h. With SAHA, we observed
similar effects for acetyl-α-tubulin, but histone H4 acetyl-
ation was maintained at a later time (Fig. 3b).
MAKV-8 displayed cytotoxic properties in CML cells
We further evaluated whether MAKV-8 treatments
exert anti-CML properties. MAKV-8 inhibited the
growth of CML cell lines (i.e., K-562, KBM-5, and
MEG-01) starting at about 3 μM, and cell death was
Fig. 2 MAKV-8 inhibits HDAC activities in vitro and binds to the ligand-binding pocket of HDAC isoenzymes. (a) In vitro HDAC activity assays
were conducted with increasing MAKV-8 concentrations. Relative activities of total HDAC, HDAC1, and HDAC6 were determined by comparison
to the vehicle, DMSO. (b) Docking poses of MAKV-8 (stick model, orange) on the crystal structure of indicated HDAC isoenzymes (white; PDB
codes: see Methods section). Numbered residues forming hydrophobic interactions in the binding sites (stick representation) correspond to
HDAC1 to HDAC8 from top to bottom. Zinc atom is shown as a purple sphere; nitrogen and oxygen are colored in blue and red, respectively
Lernoux et al. Clinical Epigenetics           (2020) 12:69 Page 4 of 26triggered beginning at 10 μM after 48 h of treatment
(Fig. 3c). Accordingly, the replicative ability of CML
cells in a 3D model was strongly reduced by MAKV-8,
beginning at 5 μM in K-562 and MEG-01 cells and





Lipinski’s rule of five Volume (Å3) NA
miLogP ≤ 5
MW (Da) ≤ 500
n-OHNH ≤ 5
n-ON ≤ 10
Ghose filter n-atoms 20 ≤ × ≤ 70
Veber’s rule n-rotb ≤ 10
TPSA (Å2) ≤ 140
Absorption BBBP 0.1 ≤ MA ≤ 2
IA (%) ≥ 70
PPB (%) < 90
Toxicity Rat NA
BBBP blood-brain barrier penetration, IA intestinal absorption, MA middle absorption
number of atoms, n-OHNH number of hydrogen bond donors, n-ON number of hyd
PPB plasma protein binding, TPSA topological polar surface areaexposure also enhanced α-tubulin and histone H4
acetylation in KBM-5 and MEG-01 cells, which gener-
alized our findings concerning MAKV-8-mediated in-
hibition of multiple HDAC activities in CML cells
(Fig. 3e).ailability
MAKV-8 SAHA PXD-101 LBH-589
411.02 255.64 266.11 330.62
3.49 2.47 2.19 3.19
446.5 264.32 318.35 349.43
4 3 3 4
10 5 6 5
32 19 22 26
12 8 5 7
142.79 78.42 95.5 77.14
0.12 0.22 0.18 1.16
76.68 84.53 89.94 89.23
82.82 72.16 94.26 78.3
Negative Negative Negative Negative
, miLogP octanol-water partition coefficient, MW molecular weight, n-atoms
rogen bond acceptors, n-rotb number of rotatable bonds, NA not applicable,
Table 2 Qualitative molecular docking of MAKV-8 against
selected HDACs
HDAC (PDB code) MAKV-8 SAHA
HDAC1 (4BKX) − 6.7 − 5.4
HDAC2 (4LY1) − 7.2 − 6.7
HDAC3 (4A69) − 6.9 − 6.5
HDAC4 (2VQM) − 7.7 − 5.6
HDAC6 (5EDU) − 7.2 − 6.1
HDAC7 (3C10) − 7.1 − 6.0
HDAC8 (3EW8) − 7.0 − 6.9
Average − 7.1 − 6.2
Binding affinity energy values (kcal/mol) for the indicated Protein Data Bank
(PDB) codes were calculated using AutoDock Vina program. SAHA was used as
a reference HDACi
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compound
To gain insight into the relationship between MAKV-8
structure and deacetylase-inhibiting activities, we tested
the HDAC-inhibitory potential of four MAKV-8 deriva-
tives (Fig. 1). In vitro, IC50 values for MAKV-6 and
MAKV-7 against total HDAC activities were in the low
micromolar range (Table 4), indicating that compounds
were less potent than MAKV-8, whereas MAKV-10 and
MAKV-12 failed to inhibit HDAC activities with con-
centrations up to 100 μM (Additional file 1: Figure S2).
Compared to MAKV-8, docking analysis showed weaker
binding affinities of the derivatives to HDAC6; MAKV-6
and MAKV-7 could not bind properly to its ligand-
binding pocket, whereas MAKV-10 and MAKV-12 mod-
erate binding did not allow suitable interactions with the
zinc atom (Fig. 4a; Table 5). We confirmed these results
in K-562 cells by showing that MAKV-6 and MAKV-7
increased histone H4 acetylation only at the highest con-
centrations and failed to increase α-tubulin acetylation,
suggesting that HDACs targeting histones were prefer-
entially inhibited, but with a much lower potency than
MAKV-8. Conversely, MAKV-10 and MAKV-12 did not
augment protein target acetylation levels even at the
highest concentrations tested (Fig. 4b). After 48 h of
treatment with MAKV-8 derivatives, we detected a reduc-
tion in K-562 cell proliferation starting at 5 μM MAKV-6
or 10 μM MAKV-7 and a decrease of cell viability starting
at 25 μM MAKV-6 or MAKV-7. In contrast, neither
MAKV-10 nor MAKV-12 impacted K-562 cell prolifera-
tion and viability (Fig. 4b), suggesting that MAKV-8 anti-
cancer effects are associated with the inhibition of HDACs
targeting histones.
MAKV-8 induced cell cycle arrest and apoptotic cell death
in CML cells
Next, we further characterized the cytostatic and cytotoxic
properties of MAKV-8 in CML cells. Since MAKV-8treatment hampered CML cell proliferation, we studied its
effects on cell cycle distribution, which revealed a time-
dependent accumulation of cells in the G1 phase, which
was comparable to results obtained with SAHA (Fig. 5a).
Nuclear morphology analyses showed that MAKV-8
mainly triggered a time- and dose-dependent increase in
apoptotic cells, which was completely prevented upon
treatment with the pan-caspase inhibitor z-VAD-FMK
(Fig. 5b). In addition, cleavage of pro-caspases 3, 7, 8,
and 9 and poly (ADP-ribose) polymerase (PARP)-1 was
consistent with caspase-dependent apoptosis induction
(Fig. 5c).
MAKV-8 triggered ER stress, autophagic flux, and DNA
damage
Since the inhibition of cell cycle progression could result
from endoplasmic reticulum (ER) stress-induced unfolded
protein response (UPR) activation [16], we analyzed 78
kDa glucose-regulated protein (GRP78) expression levels
in K-562 cells upon treatments with MAKV-8 compared
to thapsigargin. GRP78 expression was upregulated after 8
h of treatment and accompanied by increased ATF6 ex-
pression, as well as phosphorylated protein kinase RNA-
like ER kinase (PERK) and eukaryotic initiation factor
(eIF)2α levels (Fig. 6a). Accordingly, we also observed en-
hanced DNA damage-inducible transcript (DDIT)3
mRNA expression after 24 h (Fig. 6b) and X-box binding
protein (XBP)1 mRNA splicing after 4 h (Fig. 6c) upon
treatment with 10 μM MAKV-8. Altogether, results dem-
onstrate that MAKV-8 activates the UPR signaling.
Modulations of the autophagic machinery, which can
be activated by the UPR pathways [17], may contribute
to HDACi anti-cancer effects [18]. Cell morphology ana-
lyses revealed that, unlike control cells, MAKV-8-treated
cells displayed a swollen cytoplasm enriched with numer-
ous vacuoles of various sizes (Fig. 7a). Additionally, Cyto-
ID®-stained cell quantification showed that the autophagic
signal area per nucleus was about 1.5 times higher in
MAKV-8-treated cells compared to controls (Fig. 7b). Fur-
thermore, MAKV-8 treatment stimulated microtubule-
associated protein 1 light chain (LC)3-I to LC3-II conver-
sion and reduced p62/sequestosome (SQSTM)1 expres-
sion levels. Upon addition of late-phase autophagy
inhibitor bafilomycin A1, LC3-II and p62/SQSTM1 accu-
mulation was further enhanced, suggesting that MAKV-8
induced autophagy (Fig. 7c). Accordingly, the study of
cellular structures by transmission electron micros-
copy showed a more extensive autophagocytic vacuoliza-
tion in MAKV-8-treated cells compared to untreated cells
(Fig. 7d).
HDACi treatments reportedly cause DNA damage, in-
cluding double strand breaks, which partly underlies
apoptosis induction [19]. Accordingly, we showed that 5
μM MAKV-8 enhanced H2AX phosphorylation (γH2AX)
Fig. 3 (See legend on next page.)
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Fig. 3 The potent pan-HDAC inhibitor MAKV-8 displays cytotoxic properties in CML cells. The acetylation levels of HDAC targets were assessed by
western blot in K-562 cells treated with (a) increasing MAKV-8 concentrations for 24h or (b) 15µM MAKV-8 for the indicated time points. (c) CML
cell proliferation and viability were evaluated following treatments with increasing MAKV-8 concentrations for up to 72h. (d) CML cells were
grown in the presence of increasing MAKV-8 concentrations for 10 days, and their colony-forming capacity was scored after MTT addition.
Representative pictures (left panel) and corresponding quantifications (right panel) from three independent experiments are provided. (e) Histone
H4 and α-tubulin acetylation levels were assessed by western blot in KBM-5 and MEG-01 cells treated with increasing MAKV-8 concentrations for
24h. β-actin and histone H1 served as loading controls for α-tubulin and histone H4, respectively. Blots are representative of three independent
experiments. SAHA was used as a reference HDACi
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μM MAKV-8 (Fig. 7e), although less important than that
observed with cisplatin [20].Modulation of HDAC expression profiles in CML patients
Despite the outstanding therapeutic results obtained with
TKis in CML, the occurrence of imatinib resistance in
over 30% of CML patients necessitates the discovery of
additional therapeutic approaches. Interestingly, transcrip-
tomic analyses of CML patient data revealed that HDAC1
and HDAC2 mRNA expression levels were significantly
upregulated and associated with a trend towards increased
HDAC3 mRNA levels in LSCs compared to healthy stem
cells (HSCs) (Fig. 8a). The importance of HDAC1 and
HDAC2 in tumor cell survival provides a good rational for
treating CML cells with imatinib in combination with
pan-HDACis [21].Table 4 In vitro HDAC-inhibitory activity of MAKV-8 and derived
compoundsMAKV-8 combined with imatinib displayed synergistic
pro-apoptotic activity in imatinib-sensitive and imatinib-
resistant CML cells
Considering computational docking results, we investi-
gated the anti-leukemic potential of co-treatments with
subtoxic concentrations of MAKV-8 and imatinib in
imatinib-sensitive and imatinib-resistant CML cells.
First, we tested whether treatment with imatinib affected
MAKV-8-mediated HDAC inhibition. In all CML cells,
α-tubulin acetylation was similarly induced after a 24-h
exposure to MAKV-8-imatinib co-treatment compared
to MAKV-8 treatment alone, whereas acetylated histone
H4 levels were further enhanced. In contrast, cells




Acetyl α-tubulin 12.1 ± 0.9 1.9 ± 0.8
Acetyl histone H4 5.9 ± 1.4 2.6 ± 0.2
Data are presented as the mean ± standard deviation of the effective
concentration that induces half-maximal acetylation of protein targets (EC50).
Values were calculated after western blot quantification from at least three
independent experiments. Concentrations of compounds near the EC50 values
have been used for subsequent experimentsincreased levels of acetylated α-tubulin and histone H4,
respectively, compared to SAHA alone (Fig. 8b).
We then evaluated the effect of combinations on CML
cell viability. In K-562 cells, MAKV-8-imatinib-mediated
reduction in viability was greater than that induced by
compounds alone, with a 75%-decrease in living cells
after treatment with 10 μM MAKV-8 combined with
imatinib (Fig. 9a). Combination index (CI) values below
1 indicated synergism for each MAKV-8 concentration
combined with imatinib, with the highest MAKV-8
concentration conferring the maximal effect (Table 6). Add-
itionally, MAKV-8-imatinib co-treatment triggered mito-
chondrial membrane potential (MMP) loss and increased
Annexin V-positive cell proportion, reaching approximately
83% of cells displaying low MMP and Annexin V positivity,
respectively, after co-treatments with 10 μM MAKV-8
compared to 7 and 20% in untreated cells (Fig. 9b, c). Such
co-treatment also caused a stronger cleavage of caspases 3,
8, 9, and PARP-1, indicating more important apoptosis in-
duction than observed with single treatments (Fig. 9d).
We generalized our findings by showing that MAKV-8-
imatinib combination also had a synergistic effect on KBM-
5 and MEG-01 cell viability, with a reduction of 88 and
69% of living cells, respectively, following co-treatments
with the highest MAKV-8 concentration (Fig. 10a, upper
panel, Table 6). Additionally, caspase 3 and PARP-1 cleav-
age highlighted a greater induction of apoptosis in MAKV-
8-imatinib co-treated KBM-5 and MEG-01 cells (Fig. 10a,
lower panel). Comparatively, co-treatments with 2 μM
SAHA presented similar results to those obtained after co-Compounds IC50 values against total HDAC activity (nM)
MAKV-6 1050 ± 220
MAKV-7 22,000 ± 25,200
MAKV-8 5.8 ± 3.8
MAKV-10 > 100,000
MAKV-12 > 100,000
Data are presented as the mean ± standard deviation of the concentration
inhibiting 50% (IC50) of the HDAC activity. Values were calculated from at least
three independent experiments or two independent experiments for MAKV-10
and MAKV-12
HDAC histone deacetylase
Fig. 4 (See legend on next page.)
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Fig. 4 MAKV-8 derivatives display lower potency than their parent compound. (a) Docking poses of MAKV-8 derivatives (stick model) on HDAC6
crystal structure (white; PDB code: 5EDU). Numbered residues forming hydrophobic interactions in the binding sites (stick representation) are
indicated. Zinc atom is shown as a purple sphere; nitrogen and oxygen are colored in blue and red, respectively. (b) Histone H4 and α-tubulin
acetylation levels were assessed by western blot (upper panel), and cell proliferation and viability were evaluated (lower panel) following
treatments of K-562 cells with increasing concentrations of the indicated MAKV-8 derivatives for 24h and up to 72h, respectively. β-actin and
histone H1 served as loading controls for α-tubulin and histone H4, respectively. Blots are representative of three independent experiments. SAHA
was used as a reference HDACi
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CML cells (Figs. 9 and 10a).
In imatinib-resistant KBM-5 (KBM-5R) cells, which
began to die in response to a dose between 10 and 25
μM imatinib (Additional file 1: Figure S3), the decrease
in cell viability was further enhanced by co-treatments
compared to treatments with either drug alone, and a
synergistic loss of 65% of living cells occurred after a
combination with 2.5 μM MAKV-8 and 10 μM imatinib
(Fig. 10b, upper panel; Table 6). Accordingly, PARP-1
cleavage, which indicated the activation of apoptotic path-
ways, was stronger in co-treated KBM-5R cells (Fig. 10b,
lower panel).
Imatinib-MAKV-8 co-treatment induced differential
toxicity in healthy cell models compared to CML cells
Next, we evaluated the effect of MAKV-8-imatinib co-
treatments on the viability of healthy cell models. In per-
ipheral blood mononuclear cells (PBMCs), we observed
a moderate effect with MAKV-8 treatment either alone
or in combination, with a maximum decrease of 30% of vi-
able cells after 48 h, whereas imatinib alone failed to trigger
any cell mortality (Fig. 11a, upper panel; Additional file 1:
Figure S4). These results were comparable to those of
SAHA (Additional file 1: Figure S4). Although RPMI-1788
cells underwent a reduction of about 55% of living cells
following a 48-h treatment with 10 μM MAKV-8, the de-
crease in cell viability was not further enhanced upon
addition of imatinib (Fig. 11a, lower panel). Conse-
quently, the ratio of cell death induced by MAKV-8-
imatinib co-treatments in cancer versus normal cells
attested of a stronger toxicity against cancer cells
(Table 7). Finally, MAKV-8 neither alone nor in co-Table 5 Qualitative molecular docking of MAKV-8 derivatives
against HDAC6






aBinding affinity energy values for Protein Data Bank (PDB) code 5EDU were
calculated using AutoDock Vina programtreatments elicited any significant cytotoxicity in plate-
lets (Fig. 11a, right panel; Additional file 1: Figure S4).
Altogether, combination of MAKV-8 with imatinib dis-
played a promising safety profile for healthy cells.
Finally, we investigated the ability of CML cell lines
pre-treated with MAKV-8 for 8 h to form colonies in
the presence of experimentally selected imatinib concen-
trations (Additional file 1: Figure S5). The combinations
exerted more potent effects on reducing colony forma-
tion than agents alone in both imatinib-sensitive and
imatinib-resistant CML cells (Fig. 11b).
Beclin-1 knockdown partially prevented MAKV-8-imatinib
combination-induced apoptosis
Since MAKV-8 treatments induced autophagy, we tested
whether this process would be implicated in co-
treatment-induced synergistic cell death. We knocked
down the gene coding for beclin-1 (BECN1) (Fig. 12a)
and observed after 48 h of MAKV-8-imatinib treatment
that the proportion of viable K-562 cells was significantly
increased from 15 and 20% in cells transfected with or
without non-targeting small interfering RNA (siRNA),
respectively, to 40% in BECN1-silenced cells (Fig. 12b,
upper panel). Finally, decreased PARP-1 cleavage in cells
transfected with siRNA targeting BECN1 further con-
firmed reduced apoptotic rate (Fig. 12b, lower panel).
MAKV-8 and imatinib co-treatment reduced BCR-ABL-
related pathways
BCR-ABL-related signaling pathways result in CML cell
growth and survival [22]. Accordingly, we examined the
effects of MAKV-8-imatinib co-treatment on the expres-
sion and phosphorylation of BCR-ABL and downstream
targets in K-562 cells. Although such combination did
not impact BCR-ABL expression, it led to a drastic de-
crease in its phosphorylation accompanied by a similar
effect on signal transducer and activator of transcription
(STAT)5 phosphorylation. Notably, MAKV-8 further
downregulated STAT5 protein levels and provoked a
striking decrease in c-MYC expression, which was main-
tained by co-treatment with imatinib. Conversely, mye-
loid cell leukemia (MCL)-1 expression was not markedly
impacted by the combination due to oppositional effects
exhibited by each drug (Fig. 12c). Despite a MAKV-8-
mediated upregulation in BCR-ABL expression, treatment
Fig. 5 (See legend on next page.)
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Fig. 5 Treatment with MAKV-8 leads to cell cycle arrest and apoptotic cell death. K-562 cells were treated with MAKV-8 at the indicated time
points and concentrations, followed by analyses of (a) cell cycle distribution using a range of subtoxic cytostatic MAKV-8 concentrations to focus
only on aspects of cell cycle modulation, (b) nuclear morphology, and (c) caspase and PARP-1 activation. (b) Representative pictures of cells
stained with Hoechst in blue and propidium iodide (PI) in red (upper left panel) and corresponding quantifications (lower right panel) from three
independent experiments are provided. Where indicated, cells were pre-incubated for 1h with the pan-caspase inhibitor z-VAD-FMK. Cisplatin was
used as a positive control for caspase and PARP-1 cleavage. Blots used β-actin as the loading control and are representative of three independent
experiments. SAHA was used as a reference HDACi
Fig. 6 MAKV-8 treatment induces ER stress. K-562 cells were treated with the indicated concentrations of MAKV-8 at the indicated time points
unless otherwise stated. (a) The expression levels of UPR-associated proteins, such as the ER stress marker GRP78, were assessed by western blot
using β-actin as a loading control. (b) DDIT3 mRNA expression levels were quantified by real-time PCR and normalized to β-actin mRNA levels. (c)
End-point analysis of XBP1 mRNA splicing. Thapsigargin (T, 4 µM) was used as a positive control for ER stress induction. All pictures are
representative of three independent experiments
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Fig. 7 MAKV-8 treatment triggers autophagy and double strand breaks. K-562 cells were treated with the indicated concentrations of MAKV-8 at
the indicated time points unless otherwise stated. (a) Cell morphology was analyzed after 48h of treatment using modified GIEMSA staining, and
pictures were acquired by bright-field microscopy. (b) The appearance of autophagosome-related vesicles was quantified in cells treated with
MAKV-8 for 8h. Representative pictures of cells stained with Hoechst in blue and Cyto-ID in green (left panel) and corresponding quantifications
(right panel) from three independent experiments are provided. (c) After 8h of treatment, the conversion of LC3-I to LC3-II and expression of p62,
two autophagic markers, were evaluated by western blot. Where indicated, bafilomycin A1 was added 2h before the end of treatment. (d)
Representative images of electron microscopy analysis in indicated CML cell line: (1) phagophores and (2) autophagolysosomes. (e) The
expression level of γH2AX, the earliest marker for DNA damage localized at double strand breaks, was assessed by western blot. Cisplatin (C, 50
µM) was used as a positive control for double strand break induction. Blots used β-actin as the loading control, and pictures are representative of
three independent experiments
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phosphorylation in KBM-5, MEG-01, and KBM5-R cells
(Fig. 12d). In all CML cell lines, treatments with SAHA,
alone or in combination with imatinib, exhibited results
comparable to that of the highest MAKV-8 concentration
(Fig. 12c, d).
MAKV-8 and imatinib co-treatment reduced the LSC
population and inhibited CML cell growth in vivo
The oncogenic transcription factor c-MYC reportedly
plays an important role in LSC survival, which is impli-
cated in TKi resistance and relapse in CML patients
[23]. Moreover, bioinformatic analysis revealed that c-
MYC mRNA expression levels were significantly upregu-
lated in LSCs versus HSCs (Fig. 13a).
Since MAKV-8 strongly reduced c-MYC expression
(Fig. 12c), we further evaluated whether MAKV-8 treat-
ment, with and without imatinib, could decrease the al-
dehyde dehydrogenase (ALDH)+ LSC fraction in K-562
cells. The ALDH+ cell percentage was reduced from 50%
in untreated cells to 24 and 30% in MAKV-8- and
imatinib-treated cells, respectively, and was further de-
creased to 15% after MAKV-8-imatinib co-treatment. In
contrast, SAHA failed to reduce the ALDH+ cell propor-
tion. When cells were co-treated with SAHA and ima-
tinib, the percentage of ALDH+ cells decreased to 30%,
indicating the MAKV-8-imatinib combination was more
efficient to reduce LSC population (Fig. 13b).
We finally tested our findings in an in vivo setting and
demonstrated that combining MAKV-8 with imatinib
fully abrogated tumor formation in zebrafish xenografted
with K-562 cells, whereas single agents were unable to
significantly reduce tumor volumes (Fig. 13c; Additional
file 1: Figure S6).
Discussion
In vitro, MAKV-8 acts as 10 times more potent pan-
HDACi than SAHA. Accordingly, docking studies sug-
gest efficient MAKV-8 interactions with the ligand-
binding pockets of all tested HDACs, with higher bind-
ing affinity in comparison to SAHA. Interestingly, EC50
values for MAKV-8 and SAHA towards acetylated pro-
tein targets, as well as the different modulations ofcompounds-mediated HDAC inhibition upon imatinib
addition suggest distinct HDAC-inhibitory properties.
Compared to SAHA, MAKV-8-mediated acetylation of
specific histone and non-histone proteins may result in
improved HDACi-related anti-cancer activities. Despite
a fairly good overall in silico profile, some structural
modifications could be necessary to improve MAKV-8
drug-likeness parameters. Nevertheless, the importance
of the hydroxamate group and the linker chain length
for HDAC-inhibitory activities was confirmed by the re-
sults obtained with MAKV-8 derivatives [15]. Notably,
in silico predictions should be critically considered due
to potentially different pharmacokinetic properties of
compounds in vivo. Collectively, MAKV-8 appears to be
an attractive drug candidate for further consideration in
CML therapies, especially considering that the inhibition
of HDAC1 and HDAC2, upregulated in LSCs versus
HSCs from patients, strongly impacts the transcription
of proteins essential for tumor cell survival [21].
MAKV-8 treatment triggers ER stress, as evidenced by
the upregulation of proteins related to UPR. Since
HDACs have been described to modulate GRP78 acetyl-
ation [24], MAKV-8-mediated HDAC inhibition could
result in GRP78 acetylation and selective UPR activation,
as similarly reported for other HDACi [25]. Further-
more, MAKV-8-mediated inhibition of HDAC6, which
is important for misfolded protein clearance, could thus
lead to the accumulation of protein aggregates and ER
stress induction [26]. Simultaneously to ER stress,
MAKV-8 induces autophagy. Pan-HDACi have been
shown to promote the initiation and block the matur-
ation phases of autophagy by inhibiting class I–IIa and
class IIb HDACs, respectively [27]. Autophagy may also
participate in imatinib sensitization, as downregulation
of pro-autophagic beclin-1 expression partly prevents
co-treatment-induced cell death. Conversely, one study
showed that impairing autophagy significantly enhanced
SAHA anti-cancer activity [28]. Finally, MAKV-8 treat-
ment weakly induces the appearance of double strand
breaks at a time where no cell death is observed. Since
H2AX phosphorylation does not occur in concomitance
with histone acetylation, as previously reported [29],
MAKV-8-mediated accumulation of excessive DNA
Fig. 8 Treating CML cells with imatinib in combination with pan-HDACis is a promising therapeutic approach. (a) Boxplots including outliers
illustrating fold-change (log2) of HDAC1, HDAC2 and HDAC3 mRNA expression levels in CD34+CD38- stem cells isolated from healthy (n=7) and
CML (n=11) patients (represented by triangles). (b) CML cells were treated with the indicated concentrations of imatinib alone or in combination
with MAKV-8. After 24h-incubations, α-tubulin and histone H4 acetylation levels were assessed by western blot, with β-actin and histone H1 as
loading controls, respectively. Blots are representative of three independent experiments. SAHA was used as a reference HDACi
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Fig. 9 The HDACi MAKV-8 combined with imatinib induces synergistic anti-cancer activity in K-562 cells. Cells were treated with the indicated
concentrations of imatinib alone or in combination with MAKV-8. (a) Nuclear morphology, (b) phosphatidylserine exposure, and (c) mitochondrial
membrane potential (MMP) were analyzed in K-562 cells treated for 48h. Representative dot plots (left panel) and corresponding quantifications
(right panel) from three independent experiments are provided. (d) Caspase and PARP-1 cleavages were analyzed by western blot in K-562 cells
treated for 24h, using β-actin as the loading control. Cisplatin was used as a positive control for apoptosis induction and MMP disruption. Blots
and pictures are representative of three independent experiments. SAHA was used as a reference HDACi
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and this accumulation could lead to apoptosis activation
[30]. Altogether, our work does not exclude that
MAKV-8-related mechanisms could be implicated in its
cytotoxic effects, but further studies are required. Im-
portantly, the lack of differential toxicity in CML versus
healthy cells following MAKV-8 treatment strongly
limits its use as a monotherapy. Nevertheless, the treat-
ment of cancer patients with single agents is increasingly
replaced by combination therapies to prevent adaptive
response and acquired drug resistance [31].
In imatinib-sensitive and imatinib-resistant BCR-ABL-
positive CML cells, synergistic apoptotic cell death is
triggered upon MAKV-8-imatinib co-treatment. Accord-
ingly, concomitant treatment with SAHA and TKi has
previously been reported to synergistically induce apop-
tosis in CML cell lines [13, 14]. Furthermore, MAKV-8
combined with imatinib also impaired tumor growth of
xenografted CML cells in zebrafish, which is considered
as an appropriate vertebrate model organism owing to
the high percentage of orthologous genes between zebra-
fish and humans [32]. Notably, moderate cytotoxicity
was observed in healthy models exposed to the same co-
treatment. A weak toxicity towards normal cells compared
to cancerous cells has also been described for many other
HDACi [33, 34]. Collectively, MAKV-8 could provide a
non-toxic strategy for overcoming imatinib resistance,
hence providing a rational basis to further study the po-
tency of MAKV-8-imatinib combination for CML therapy.Table 6 Combination index (CI) values for treatments with
combined MAKV-8-imatinib in imatinib-sensitive and imatinib-
resistant CML cells
Cell line MAKV-8 (μM) Imatinib (μM) CI (48 h)a
K-562 5 0.25 0.42 ± 0.13
10 0.25 0.28 ± 0.14
KBM-5 1 2.5 0.46 ± 0.06
2.5 2.5 0.05 ± 0.03
MEG-01 5 0.25 0.77 ± 0.16
10 0.25 0.37 ± 0.07
KBM-5R 1 10 1.42 ± 0.58
2.5 10 0.78 ± 0.16
aCI values correspond to the mean ± standard deviation of three independent
Hoechst-propidium iodide staining experiments
CML chronic myeloid leukemiaMechanistically, lowered BCR-ABL kinase activity is
observed after MAKV-8-imatinib co-treatment, which
most likely explains the reduction in STAT5 phosphoryl-
ation, as well as the drop in c-MYC and MCL-1 expression.
Previous reports indicate that SAHA downregulates BCR-
ABL mRNA and protein levels in CML cells [13], which
could be implicated in synergistic anti-leukemic interactions
involving TKis [14]. By inhibiting HDAC6, pan-HDACis
could disrupt the association of HSP90α with BCR-ABL, pro-
voking its poly-ubiquitination and proteasomal degradation
[35]. Surprisingly, MAKV-8 rather augments BCR-ABL ex-
pression in our cell models, implying the involvement of
other regulatory mechanisms. Furthermore, downstream
BCR-ABL targets play a critical role in CML pathogenesis
[36–38]. Similar to our observations, HDACi-mediated
potentiation of TKi cytotoxicity has been related to STAT5
inhibition in BCR-ABL-positive cells [39]. As previously de-
scribed, HDACi-related apoptosis induction in CML cells
could be enhanced by imatinib-mediated downregulation of
anti-apoptotic MCL-1 expression, which was upregulated by
MAKV-8 [40]. In addition, c-MYC has been recently re-
ported as an important target for selectively eliminating
CML LSCs [41]. Accordingly, human LSCs displayed in-
creased c-MYC mRNA levels compared to HSCs. Besides
lowering c-MYC expression, MAKV-8 treatment potently
decreased the ALDH+ cell proportion, which was further
enhanced upon co-treatment with imatinib. Altogether,
combining imatinib with MAKV-8, which targets key
hematopoietic stem cell molecular effectors, may represent
an effective strategy to overcome LSC resistance to TKis,
thereby offering the opportunity to improve disease out-
comes for CML patients.
Conclusions
We found that compound MAKV-8 acted as a potent
pan-HDACi in vitro and in various CML cell lines. Fur-
thermore, MAKV-8 in combination with imatinib dis-
played promising anti-cancer properties in imatinib-
sensitive and imatinib-resistant BCR-ABL-positive CML
cells, whereas only a very moderate toxicity was noted in
healthy cell models exposed to the same co-treatment.
Mechanistically, the combination MAKV-8-imatinib
reduced BCR-ABL expression and phosphorylation, as
well as the expression of downstream targets playing a
critical role in CML proliferation and survival. In
addition, such therapeutic approach effectively decreased
Fig. 10 MAKV-8 combined with imatinib induces synergistic anti-cancer activity in imatinib-sensitive and -resistant CML cells. CML cells were
treated with the indicated concentrations of imatinib alone or in combination with MAKV-8. (a) Nuclear morphology (upper panel) and cleavage
of caspase 3 and PARP-1 (lower panel) were studied in KBM-5 and MEG-01 cells treated for 48 and 24h, respectively. (b) Nuclear morphology
(upper panel) and PARP-1 cleavage (lower panel) were evaluated in KBM-5R cells treated for 48 and 24h, respectively. Caspase and PARP-1
cleavages were assessed by western blot using β-actin as the loading control. Cisplatin was used as a positive control. Blots are representative of
three independent experiments. SAHA was used as a reference HDACi
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Fig. 11 MAKV-8 combined with imatinib displays a differential toxicity in healthy cells compared to CML cells. CML and healthy cells were treated
with the indicated concentrations of imatinib alone or in combination with MAKV-8. (a) Healthy cell models were treated for 48h. Cell viability was
assessed based on the Trypan Blue exclusion method for PBMCs, by flow cytometry after Annexin V staining for platelets, and nuclear morphology
was examined in RPMI-1788 cells. SAHA was used as a reference HDACi. (b) CML cells were pre-treated with MAKV-8 for 8h and then grown in
semisolid methylcellulose medium in the presence of imatinib. After 10-day incubations, cell colony-forming capacity was scored after MTT addition.
Representative pictures (left panel) and corresponding quantifications (right panel) from three independent experiments are provided
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that treatment with MAKV-8 contributes to a strong
sensitization of imatinib-sensitive and imatinib-resistant
CML cells including LSCs towards imatinib cytotoxicity,
hence providing a rational basis to further study the po-
tency of MAKV-8 and imatinib as a combination ther-
apy against CML.
Methods
Cell culture and reagents
The human CML cell lines K-562 (DSMZ Cat# ACC-10,
RRID: CVCL_0004) and MEG-01 (DSMZ Cat# ACC-
364, RRID: CVCL_0425) were purchased from Deutsche
Sammlung für Mikroorganismen und Zellkulturen
(Braunschweig, Germany). Human CML KBM-5 cells
were kindly provided by Dr. Bharat B. Aggarwal.
Imatinib-resistant KBM-5 (KBM-5R) cells were estab-
lished as previously described [42]. The K-562, MEG-01,
and KBM-5 cell lines have been authenticated in 2014
using the LGC Standards Cell Line Authentication ser-
vice (Teddington, UK). All cells were maintained at 37
°C in a humid atmosphere and 5% CO2 in a culture
medium supplemented with 10% heat-inactivated fetal calf
serum (FCS; BioWhittaker ®, Lonza, Verviers, Belgium) and
1% (v/v) antibiotic (streptomycin and penicillin) and anti-
mycotic (BioWhittaker®). K-562 and MEG-01 cells were
cultured in RPMI 1640 medium (BioWhittaker®). KBM-5
and KBM-5R cells were cultured in IMDM medium
(BioWhittaker®).
PBMCs were isolated from the blood of healthy
adult human donors obtained from the Red Cross
(Luxembourg, Luxembourg) and purified as previously
reported [43]. Human RPMI-1788 cells (ATCC Cat#
CCL-156, RRID: CVCL_2710), which were derived
from B lymphocytes, were purchased in 2017 fromTable 7 Selectivity ratio of MAKV-8-imatinib co-treatment for








Values were calculated from the percentage of cancer cell death versus
healthy cell death from three independent experiments
PBMCs peripheral blood mononuclear cellsthe American Type Culture Collection (Manassas,
Virginia, USA). Platelets from healthy adult human
donors were provided by the Red Cross. All healthy
models were cultured at 37 °C in a humid atmos-
phere and 5% CO2 in RPMI 1640 medium (BioWhit-
taker®) supplemented with 0, 10, or 20% heat-
inactivated FCS (BioWhittaker®) for platelets, PBMCs,
and RPMI-1788 cells, respectively, and each con-
taining 1% (v/v) antibiotic-antimycotic
(BioWhittaker®).
All cell lines have been monthly tested for myco-
plasma contamination.
Compound MAKV-8 was synthetized as previously de-
scribed by Kozikowski et al. (compound 3) [15], and com-
pounds MAKV-6, MAKV-7, MAKV-10, and MAKV-12
were derived from the reported synthetic protocol as shown
in Additional file 1: Figure S7. The following additional
compounds were used in this study: cisplatin in saline solu-
tion from Teva Pharmaceutical Industries Ltd. (Wilrijk,
Belgium), imatinib and thapsigargin from Sigma-Aldrich
(Bornem, Belgium), SAHA from Cayman Bio-connect
(Huissen, Netherlands), and z-VAD-FMK from Millipore
(Merck, Brussels, Belgium). Except for cisplatin, all com-
pounds were dissolved in dimethylsulfoxide (DMSO).Computational analysis of public chronic myeloid
leukemia datasets
The gene expression microarray datasets E-MTAB-2581
[44] and GSE97562 [45] were downloaded from the
ArrayExpress database [46] and the Gene Expression
Omnibus repository, respectively. Datasets were normal-
ized using the Robust Multichip Average algorithm from
the oligo R package (version 1.48.0) [47] and batch cor-
rected using the function removeBatchEffect from the
limma R package (version 3.40.2) [48]. The ggboxplot
function from the ggpubr package (version 0.2.1) [49]
was used to draw the boxplots in R 3.6.0 [50] and RStu-
dio [51].In vitro HDAC activity assay
In vitro HDAC activities were measured as previously
described [52, 53]. IC50 values against the various HDAC
activities were determined using nonlinear regression in
Prism 8.0 software (GraphPad Software, Inc., La Jolla,
CA, USA).
Fig. 12 (See legend on next page.)
Lernoux et al. Clinical Epigenetics           (2020) 12:69 Page 20 of 26
(See figure on previous page.)
Fig. 12 Altered BCR-ABL signaling and autophagy induction are associated with MAKV-8-imatinib anti-cancer properties. CML cells were treated
with the indicated concentrations of imatinib alone or in combination with MAKV-8. (a, b) K-562 cells were transfected with or without the
indicated siRNA, then (a) the expression level of beclin-1, a protein involved in initiating the autophagic flux, was assessed by western blot 24
and 72h post-transfection, and (b) nuclear morphology (upper panel) and PARP-1 cleavage (lower panel) were analyzed in cells treated for 24
and 48h, respectively. The ratio between the cleaved and uncleaved forms of PARP-1 was determined based on western blot quantification. (c, d)
Protein expression and phosphorylation levels were assessed by western blot in cells treated for 24h. Blots used β-actin as a loading control and
are representative of three independent experiments. SAHA was used as a reference HDACi
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Docking studies were carried out as previously reported
[54] using the Protein Data Bank (PDB) codes 4BKX, 4LY1,
4A69, 2VQM, 5EDU, 3C10, and 3EW8 corresponding to
HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7,
and HDAC8, respectively. MAKV-6, MAKV-7, MAKV-8,
MAKV-10, and MAKV-12, and SAHA were drawn using
ChemDraw Professional software version 15.0 (PerkinElmer
Informatics).
Prediction of in silico drug-likeliness parameters
The web-based Molinspiration Cheminformatics (http://
www.molinspiration.com/products.html) and PreAD-
MET ver2.0 (https://preadmet.bmdrc.kr) programs were
used to compute compound drug-likeness parameters.
Cell viability and proliferation test
Cell viability and proliferation were evaluated using the
Trypan Blue exclusion method (BioWhittaker ®). Cells
were processed using a semi-automated image-based cell
analyzer (Cedex XS Innovatis, Roche, Luxembourg,
Luxembourg), which provided the cell number as well as
cell viability based on the fraction of trypan blue-positive
cells.
For colony formation assays, 1000 cells were grown in
1 mL of semi-solid methylcellulose medium (Methocult
H4230, StemCell Technologies Inc., Grenoble, France)
supplemented with 10% heat-inactivated FCS (BioWhit-
taker ®) in 12-well plates. Colonies were detected after
10 days of culturing by adding 5 mg/mL 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT)
reagent (Sigma-Aldrich) and incubating for 15 min at 37
°C. Pictures were taken with the GelDoc XR+ System
(BioRad, Temse, Belgium), and quantifications were con-
ducted using Image J software (US National Institute of
Health, Bethesda, MD, USA).
Protein extractions and western blotting analysis
Cells were lyzed in 10% (v/v) Mammalian Protein Extrac-
tion Reagent solution (MPER®; Thermofisher, Erembode-
gen, Belgium) supplemented with 1× protease inhibitor
cocktail (Complete EDTA-free, Roche) according to the
manufacturer’s instructions. Histone enrichment was per-
formed in acidic conditions as previously described [55].The protein concentration was determined using the
Bradford assay (BioRad).
Western blotting was performed as previously de-
scribed [53] using the following primary antibodies: acet-
ylated α-tubulin (sc-23950, RRID: AB_628409, 1/1000),
ATF6 (sc-166659, RRID: AB_2058901, 1/250), c-ABL
(sc-23, RRID: AB_626775, 1/1000), caspase 3 (sc-56053,
RRID: AB_781826, 1/1000), GRP78 (sc-13968, RRID:
AB_2119991, 1/1000), p62/SQSTM1 (sc-28359, RRID:
AB_628279, 1/1000), and phosphorylated PERK (sc-
32577, RRID: AB_2293243, 1/1000) from Santa Cruz
Biotechnology (Boechout, Belgium); phosphorylated
H2AX (05-636, RRID: AB_2755003, 1/500), acetylated
histone H4 (06-866, RRID: AB_310270, 1/50000), and
histone H1 (05-457, RRID: AB_310843, 1/2000) from
Millipore; α-tubulin (CP06, RRID: AB_2617116, 1/5000)
from Calbiochem; β-actin (A5441, RRID: AB_476744, 1/
20000) and LC3 (L7543, RRID: AB_796155, 1/1000)
from Sigma-Aldrich; beclin-1 (3738, RRID: AB_490837,
1/1000), caspase 7 (9494, RRID: AB_2068141, 1/1000),
caspase 8 (9746, RRID: AB_2275120, 1/1000), caspase 9
(9502, RRID: AB_2068621, 1/1000), eIF2α (9722, RRID:
AB_2230924, 1/2000), MCL-1 (4572, RRID: AB_
2281980, 1/1000), PARP-1 (9542, RRID: AB_2160739, 1/
1000), PERK (3192, RRID: AB_2095847, 1/1000), phos-
phorylated BCR (3901, RRID: AB_2063779, 1/1000),
phosphorylated eIF2α (3898, RRID not available, 1/
2000), STAT5 (9363, RRID: AB_2196923, 1/5000), and
phosphorylated STAT5 (9351, RRID: AB_2315225, 1/
1000) from Cell Signaling (Leiden, Netherlands); and c-
Myc (51-1485GR, RRID: AB_2148606, 1/250) from BD
Biosciences (San Jose, CA, USA). Corresponding second-
ary antibodies were obtained from Santa Cruz Biotech-
nology. Western blot quantifications were performed
with the ImageQuant TL software (GE Healthcare), and
corresponding fold change values reported to control are
indicated underneath western blot pictures, unless
otherwise specified. The EC50 values, which represent
50% of the maximum effect, were calculated using Prism
8.0 software.
Cell cycle analyses
Cells were fixed at 4 °C for 1 h with 70% ethanol and
stained for 20 min with 1 μg/mL propidium iodide in 1×
PBS supplemented with 100 μg/mL RNase A (Roche).
Fig. 13 (See legend on next page.)
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Fig. 13 MAKV-8-imatinib combination reduces cancer stem cell population. CML cells were treated with the indicated concentrations of imatinib
alone or in combination with MAKV-8. (a) Boxplots illustrating fold-change (log2) of c-MYC mRNA expression in CD34+CD38- stem cells isolated
from healthy (n=7) and CML (n=11) patients (represented by triangles). (b) Analysis of aldehyde dehydrogenase (ALDH) activity in K-562 cells
cultured for 24h and known to present a substantial proportion of cells with cancer stem-like characteristics. Elevated ALDH activity is an
established marker for the identification of hematopoietic stem cells. The ALDH inhibitor diethylaminobenzaldehyde (DEAB) was used to
distinguish cell subpopulations with low and high ALDH activity. Representative dot plots where the percentage of ALDH+ cells is indicated
(upper panel) and corresponding quantifications (lower panel) representative of three independent experiments are presented. SAHA was used as
a reference HDACi. (c) K-562 cells were treated for 24h, fluorescently labeled, and then injected into the zebrafish yolk sac. Three days post-
injection, pictures of 5 to 8 fishes (one representative set of pictures is presented) were taken, and the fluorescence intensity was quantified
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(FACS Calibur, BD Biosciences), and data were recorded
statistically (10,000 events/sample) using the CellQuest
Pro software (BD, Biosciences). The percentage of cells
in each phase of the cycle was finally determined by the
Dean-Jet-Fox algorithm using the Flow-Jo 8.8.5 software
(Tree Star, Inc., Ashland, OR, USA).
Cell death assessment
Nuclear morphology was evaluated under an IX81 (MT10)
fluorescent microscope (Olympus, Aartselaar, Belgium)
using the Cell^M software on cells incubated with 1 μg/mL
Hoechst 33342 (Invitrogen, Tournai, Belgium) for 15 min
at 37 °C and 1 μg/mL propidium iodide (Sigma-Aldrich).
Phosphatidylserine exposure was evaluated using the
FITC Annexin V Apoptosis Detection Kit I (BD Biosci-
ences) according to the supplier’s instructions. Stained
samples were processed through a cytometer (FACS
Calibur, BD Biosciences), and data were recorded statis-
tically (10,000 events/sample) using the CellQuest Pro
software (BD, Biosciences). Data were analyzed using the
Flow-Jo 8.8.5 software.
Determination of mitochondrial membrane potential
The MMP was assessed by staining with MitoTracker®
Red CMXRos (Invitrogen) according to the manufacturer’s
protocol. Stained samples (20,000 events/sample) were
processed through a cytometer (FACS Calibur, BD
Biosciences).
Assessment of gene expression
The total RNA was extracted with the NucleoSpin® RNA
Plus Kit (Macherey-Nagel, Hoerdt, France) according to
manufacturer’s instructions. Reverse transcription and
real-time PCR were performed as previously described
[56]. The following primers (Eurogentec, Liège, Belgium)
were used: β-actin (forward 5′-CTCTTCCAGCCTTC
CTTCCT-3′, reverse 5′-AGCACTGTGTTGGCGTA-
CAG-3′); DDIT3 (forward 5′-TGGAAGCCTGGTAT
GAGGAC-3′, reverse 5′-AAGCAGGGTCAAGAGTGG
TG-3′).
XBP1 splicing analysis was performed by end-point
PCR as described previously [57] using the following
primers (Eurogentec; forward: 5′- GGAGTTAAGACAGCGCTTGG -3′, reverse: 5′- ACTGGGTCCA
AGTTGTCCAG -3′).
Morphological analysis
After staining cells with the Diff-Quick Stain Kit (Dade
Behring S.A., Brussels, Belgium), morphological analyses
were performed as previously described [56].
Visualization and quantification of autophagic vesicles
For fluorescence microscopy, the Cyto-ID® Autophagy De-
tection Kit (Enzo Life Science) was used according to the
manufacturer’s instructions. Stained cells from three bio-
logical replicates were visualized under an IX81 (MT10)
fluorescent microscope. Green fluorescent autophagy-
related organelles (pre-autophagosomes, autophagosomes,
and autophagolysosomes) were quantified as green signal
area per cell nucleus as advised by the manufacturer.
Segmentation of these areas was based on 31 parameters
assessing color, texture, and edge and was carried out in
Ilastik, version 1.3.0 developed by the European Molecular
Biology Laboratory, Heidelberg [58]. Classifiers trained for
these parameters on a set of representative images were
then applied to batch process multiple images as described
in Ilastik’s user manual. Binary masks thus obtained were
measured in FIJI [59] after applying a size filter to remove
small size artifacts resulting from segmentation.
Transmission electron microscopy was performed as
previously described [60].
Evaluation of cellular ALDH activity
Cellular ALDH activity was assessed using the ALDE-
FLUORTM kit (StemCell Technologies Inc.) according to
the manufacturer’s procedure. Diethylaminobenzalde-
hyde, a specific inhibitor of ALDH activity, was used to
differentiate cells with low or high ALDH activity.
Stained samples (100,000 events/sample) were processed
through a cytometer (FACS Calibur, BD Biosciences).
Transfections
Transfections were carried out with 1.5 μL HiPerFect
Transfection reagent (Qiagen, Venlo, Netherlands) and 1
nM siRNAs (Qiagen) either targeting the human beclin-
1 gene [Hs_BECN1_2 (SI00055580)] or non-targeting
(AllStars Negative Control) as described elsewhere [61].
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medium 24 h post-transfection.
Zebrafish cancer cell xenografts
Cancer xenograft assays in zebrafish were performed as
previously described [62] using cells stained with 2 μM
CM-Dil (Invitrogen) and diluted in 1× PBS supple-
mented with 1% phenol red sodium salt solution.
Statistical analyses
All histograms represent the mean ± standard deviation
(SD) of at least 3 independent experiments. Significant
differences were determined using one-way or two-way
analyses of variance (ANOVA) followed by the Holm-
Sidak’s multiple comparison tests in the Prism 8.0 soft-
ware. Variations between patient and Cyto-ID-stained
samples were evaluated using two-tailed Welch t test in
the R 3.6.0 software and one-tailed Mann-Whitney U
test in the Prism 8.0 software, respectively. Statistical sig-
nificances were evaluated with p values below 0.05 and
are represented by the following legend: *p ≤ 0.05, **p ≤
0.01, ***p ≤ 0.001. In all experiments, data were pre-
sented as the mean ± standard deviation, and results of
treated samples were statistically compared to the corre-
sponding vehicle unless otherwise specified.
The CI was calculated according to Chou and Talalay
[63] using the Compusyn Software (ComboSyn, Inc., Pa-
ramus, NJ, USA). CI values below or above 1 indicate
synergism or antagonism, respectively, whereas the effect
is determined to be additive when the CI is equal to 1.
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